RxDoctor Payments Data

John Voss, MD

Hematology & Oncology · Meridian, MSNPI 1780793059

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.1% of the total across 1,045 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 7.5% — the pattern of someone who eats at a lot of different presentations.

$21,188in general payments, 2019–2025

Across 1,045 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AstraZeneca$2K
  • Merck$1K
  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$979
  • Pfizer$941
  • plus $13K from 54 others

What the payments were for

  • Food & beverage$20,15595%
  • Education$7534%
  • Gifts$2791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)69$1,580
AstraZeneca(2 entities)72$1,517
Merck67$1,367
Novartis63$1,134
E.r. Squibb & Sons, L.L.C.62$979
Pfizer55$941
Sanofi32$807
Amgen44$746
Incyte Corporation37$684
Gilead(2 entities)28$677
Bristol Myers Squibb33$616
Genentech USA, Inc.34$614
AbbVie18$598
Takeda Pharmaceuticals U.S.A., Inc.22$523
Regeneron Healthcare Solutions, Inc.12$436
Astellas Pharma US Inc24$427
Daiichi Sankyo Inc.19$389
Beigene USA, Inc.14$369
Eisai Inc.19$360
Lilly USA, LLC20$349
Exelixis Inc.18$321
Bayer18$302
GSK15$289
Tosoh Bioscience, Inc.1$279
EMD Serono, Inc.12$275
Rigel Pharmaceuticals, Inc.14$261
Pharmacyclics LLC, An Abbvie Company14$257
Puma Biotechnology, Inc.17$252
Karyopharm Therapeutics Inc.12$231
Myriad Genetic Laboratories, Inc.5$228
Jazz Pharmaceuticals Inc.10$226
Array Biopharma Inc11$181
Sanofi-aventis U.S. LLC6$177
Taiho Oncology, Inc.8$173
Seagen Inc.10$172
Beone Medicines USA, Inc.6$148
Boehringer Ingelheim8$130
AVEO Pharmaceuticals, Inc.6$129
Blueprint Medicines Corporation7$126
Genmab U.S., Inc.7$124
Stemline Therapeutics Inc.5$120
G1 Therapeutics, Inc.7$113
Acceleron Pharma, Inc.6$108
Ipsen Biopharmaceuticals, Inc5$106
Pharmaessentia USA Corporation4$103
Morphosys, US Inc.7$102
Coherus Oncology, Inc.5$94
Pharmacosmos Therapeutics Inc.5$88
Springworks Therapeutics, Inc.4$76
Octapharma USA, Inc.1$71
Spectrum Pharmaceuticals Inc.3$66
Tersera Therapeutics LLC3$59
Agios Pharmaceuticals, Inc.4$54
ADC Therapeutics America, Inc.3$53
Kyowa Kirin, Inc.3$46
Legend Biotech USA Inc.2$45
Secura Bio, Inc.3$43
Dova Pharmaceuticals2$36
Verastem, Inc.3$36
Lexicon Pharmaceuticals, Inc.2$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,188 in reported general payments places this provider in the 75th percentile of 57 hematology & oncology providers in Mississippi.

See all hematology & oncology providers in Mississippi

Medicare billing

Part B allowed, 2024
$4,480,932
Medicare patients
437
Services billed
220,959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide41$486,653
RevlimidLenalidomide25$422,376
ErleadaApalutamide12$206,823
LonsurfTrifluridine/Tipiracil Hcl12$158,148
EliquisApixaban46$30,400
Abiraterone Acetate21$23,760
Imatinib Mesylate50$23,497
CreonLipase/Protease/Amylase20$22,870
XareltoRivaroxaban18$15,093
Anastrozole251$4,412
Tamoxifen Citrate63$1,511
Hydroxyurea62$1,361
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen28$1,158
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen84$1,026
Dexamethasone51$895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$616$422,37625 claims
Johnson & JohnsonErleada, Xarelto$1,580$221,91630 claims
Taiho Oncology, Inc.Lonsurf$173$158,14812 claims
PfizerEliquis$941$30,40046 claims
AbbVieCreon$598$22,87020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 57 hematology & oncology providers in Mississippi.

Other hematology & oncology in Meridian

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →